Atrasentan: targeting the endothelin axis in prostate cancer

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.12, 2004-12, pp. : 1631-1640

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The IGF Axis in Prostate Cancer

Current Pharmaceutical Design, Vol. 13, Iss. 7, 2007-03 ,pp. : 719-727

Bentham Science Publishers

Access to resources Recommend Favorite

Multiple-Dose Pharmacokinetics of Atrasentan, an Endothelin-A Receptor Antagonist

By Dutta S.

Clinical Drug Investigation, Vol. 21, Iss. 2, 2001-02 ,pp. : 129-136

Adis International

Access to resources Recommend Favorite

Targeting angiogenesis for the treatment of prostate cancer

By Antonarakis Emmanuel S Carducci Michael A

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 4, 2012-04 ,pp. : 365-376

Informa Healthcare

Access to resources Recommend Favorite

Targeting Gene Therapy for Prostate Cancer

Current Pharmaceutical Design, Vol. 10, Iss. 5, 2004-01 ,pp. : 531-555

Bentham Science Publishers

Access to resources Recommend Favorite

Drug-Targeting Strategies for Prostate Cancer

Current Pharmaceutical Design, Vol. 9, Iss. 6, 2003-02 ,pp. : 455-466

Bentham Science Publishers

Access to resources Recommend Favorite